Lonafarnib - CAS# 193275-84-2 702 is potentially for the treatment

is potentially for the treatment of malaria

reduces Phospholipase A2 (PLA2) activity and sPLA2-IIA mRNA expression and mitigates LPS-induced lung injury by increasing increased Clara cell secretory protein (CCSP) expression

At 5 μM it directly inhibits DUB activity of USP9x

2014 May-Jun

26)27)9-12-19(20)22(31)29-23-28-21(14-34-23)16-5-3-2-4-6-16/h2-14

Lonafarnib - CAS# 193275-84-2 702 is potentially for the treatmentLonafarnib is a farnesyl transferase inhibitor. Structurely, it is also a synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post translational modification and activation of Ras proteins. Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated ras